Top

Published in:

01-01-2022 | Insulins | Original Article

Improved technology satisfaction and sleep quality with Medtronic MiniMed® Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial

Authors: Benjamin J. Wheeler, Olivia J. Collyns, Renee A. Meier, Zara L. Betts, Chris Frampton, Carla M. Frewen, Barbara Galland, Niranjala M. Hewapathirana, Shirley D. Jones, Denis S. H. Chan, Anirban Roy, Benyamin Grosman, Natalie Kurtz, John Shin, Robert A. Vigersky, Martin I. de Bock

Published in: Acta Diabetologica | Issue 1/2022

Abstract

Background

Automated insulin delivery aims to lower treatment burden and improve quality of life as well as glycemic outcomes.

Methods

We present sub-study data from a dual-center, randomized, open-label, two-sequence crossover study in automated insulin delivery naïve users, comparing Medtronic MiniMed® Advanced Hybrid Closed-Loop (AHCL) to Sensor Augmented Pump therapy with Predictive Low Glucose Management (SAP + PLGM). At the end of each 4-week intervention, impacts on quality of life, sleep and treatment satisfaction were compared using seven age-appropriate validated questionnaires given to patients or caregivers.

Results

59/60 people completed the study (mean age 23.3 ± 14.4yrs). Statistically significant differences favoring AHCL were demonstrated in several scales (data shown as mean ± SE). In adults (≥ 18yrs), technology satisfaction favored AHCL over PLGM as shown by a higher score in the DTSQs during AHCL (n = 28) vs SAP + PLGM (n = 29) (30.9 ± 0.7 vs 27.9 ± 0.7, p = 0.004) and DTSQc AHCL (n = 29) vs SAP + PLGM (n = 30) (11.7 ± 0.9 vs 9.2 ± 0.8, p = 0.032). Adolescents (aged 13–17yrs) also showed a higher DTSQc score during AHCL (n = 16) versus SAP + PLGM (n = 15) (14.8 ± 0.7 vs 12.1 ± 0.8, p = 0.024). The DTQ “change” score (n = 59) favored AHCL over SAP + PLGM (3.5 ± 0.0 vs 3.3 ± 0.0, p < 0.001). PSQI was completed in those > 16 years (n = 36) and demonstrated improved sleep quality during AHCL vs SAP + PLGM (4.8 ± 0.3 vs 5.7 ± 0.3, p = 0.048) with a total score > 5 indicating poor quality sleep.

Conclusion

These data suggest that AHCL compared to SAP + PLGM mode has the potential to increase treatment satisfaction and improve subjective sleep quality in adolescents and adults with T1D.

Bekiari E, Kitsios K, Thabit H, Tauschmann M, Athanasiadou E, Karagiannis T et al (2018) Artificial pancreas treatment for outpatients with Type 1 Diabetes: systematic review and meta-analysis. BMJ 361:k1310CrossRef

Collyns OJ, Meier RA, Betts ZL, Chan DSH, Frampton C, Frewen CM et al (2021) Improved glycemic outcomes with medtronic minimed Advanced Hybrid Closed-Loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with Type 1 Diabetes. Diabetes Care 44(4):969–975PubMed

Bergenstal RM, Nimri R, Beck RW, Criego A, Laffel L, Schatz D et al (2021) A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet 397(10270):208–219CrossRef

Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E et al (2020) A randomized trial of closed-loop control in children with Type 1 Diabetes. N Engl J Med 383(9):836–845CrossRef

Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP et al (2021) Extended use of the control-IQ closed-loop control system in children with Type 1 Diabetes. Diabetes Care 44(2):473–478CrossRef

Petrovski G, Al Khalaf F, Campbell J, Umer F, Almajaly D, Hamdan M et al (2021) One-year experience of hybrid closed-loop system in children and adolescents with Type 1 Diabetes previously treated with multiple daily injections: drivers to successful outcomes. Acta Diabetol 58(2):207–213CrossRef

McAuley SA, Lee MH, Paldus B, Vogrin S, de Bock MI, Abraham MB et al (2020) Six months of hybrid closed-loop versus manual insulin delivery with fingerprick blood glucose monitoring in adults with Type 1 Diabetes: a randomized. Control Trial Diabetes Care 43(12):3024–3033CrossRef

Horowitz ME, Kaye WA, Pepper GM, Reynolds KE, Patel SR, Knudson KC et al (2021) An analysis of Medtronic MiniMed 670G insulin pump use in clinical practice and the impact on glycemic control, quality of life, and compliance. Diabetes Res Clin Pract 177:108876CrossRef

Farrington C (2018) Psychosocial impacts of hybrid closed-loop systems in the management of diabetes: a review. Diabet Med 35(4):436–449CrossRef

10.

Munoz-Velandia O, Guyatt G, Devji T, Zhang Y, Li SA, Alexander PE et al (2019) Patient values and preferences regarding continuous subcutaneous insulin infusion and artificial pancreas in adults with Type 1 Diabetes: a systematic review of quantitative and qualitative data. Diabetes Technol Ther 21(4):183–200CrossRef

11.

Messer LH, Berget C, Vigers T, Pyle L, Geno C, Wadwa RP et al (2020) Real world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670G system in the first 6 months. Pediatr Diabetes 21(2):319–327CrossRef

12.

Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, Wilson DM (2019) One year clinical experience of the first commercial hybrid closed-loop system. Diabetes Care 42(12):2190–2196CrossRef

13.

Russell SJ, Beck RW (2016) Design considerations for artificial pancreas pivotal studies. Diabetes Care 39(7):1161–1167CrossRef

14.

Battelino T, Nimri R, Dovc K, Phillip M, Bratina N (2017) Prevention of hypoglycemia with predictive low glucose insulin suspension in children with Type 1 Diabetes: a randomized controlled trial. Diabetes Care 40(6):764–770CrossRef

15.

Bradley C (1994) The diabetes treatment satisfaction questionnaire (DTSQ). In: Bradley C (ed) Handbook of psychology and diabetes: a guide to psychological measurement in diabetes research and practice. Harwood Academic Publishers, Switzerland, pp 111–132

16.

Wysocki T, Reeves G, Kummer M, Ross J, Yu M (2015) Psychometric validation of the Diabetes technology questionnaire. Diabetes 64:A633-A

17.

Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ (1989) The pittsburgh sleep quality index—a new instrument for psychiatric practice and research. Psychiat Res 28(2):193–213CrossRef

18.

Raniti MB, Waloszek JM, Schwartz O, Allen NB (2018) Trinder J (2018) Factor structure and psychometric properties of the Pittsburgh Sleep Quality Index in community-based adolescents. Sleep 41(6):zsy066CrossRef

19.

Topp CW, Ostergaard SD, Sondergaard S, Bech P (2015) The WHO-5 well-being index: a systematic review of the literature. Psychother Psychosom 84(3):167–176CrossRef

20.

Gonder-Frederick LA, Schmidt KM, Vajda KA, Greear ML, Singh H, Shepard JA et al (2011) Psychometric properties of the hypoglycemia fear survey-II for adults with Type 1 Diabetes. Diabetes Care 34(4):801–806CrossRef

21.

Polonsky WH, Fisher L, Hessler D, Edelman SV (2017) Investigating hypoglycemic confidence in Type 1 and Type 2 Diabetes. Diabetes Technol The 19(2):131–136CrossRef

22.

Beato-Vibora PI, Gallego-Gamero F, Lazaro-Martin L, Romero-Perez MDM, Arroyo-Diez FJ (2020) Prospective analysis of the impact of commercialized hybrid closed-loop system on glycemic control, glycemic variability, and patient-related outcomes in children and adults: a focus on superiority over predictive low-glucose suspend technology. Diabetes Technol Ther 22(12):912–919CrossRef

23.

Pinsker JE, Muller L, Constantin A, Leas S, Manning M, McElwee Malloy M et al (2021) Real-world patient-reported outcomes and glycemic results with initiation of control-IQ technology. Diabetes Technol Ther 23(2):120–127CrossRef

24.

Barnard KD, Wysocki T, Ully V, Mader JK, Pieber TR, Thabit H et al (2017) Closing the loop in adults, children and adolescents with suboptimally controlled Type 1 Diabetes under free living conditions: a psychosocial substudy. J Diabetes Sci Technol 11(6):1080–1088CrossRef

25.

Kropff J, DeJong J, Del Favero S, Place J, Messori M, Coestier B et al (2017) Psychological outcomes of evening and night closed-loop insulin delivery under free living conditions in people with Type 1 Diabetes: a 2-month randomized crossover trial. Diabet Med 34(2):262–271CrossRef

26.

Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV et al (2016) Safety of a hybrid closed-loop insulin delivery system in patients with Type 1 Diabetes. JAMA 316(13):1407–1408CrossRef

27.

Boucher SE, Gray AR, Wiltshire EJ, de Bock MI, Galland BC, Tomlinson PA et al (2020) Effect of 6 months of flash glucose monitoring in youth with Type 1 Diabetes and high-risk glycemic control: a randomized controlled trial. Diabetes Care 43(10):2388–2395CrossRef

28.

Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA et al (2019) State of Type 1 Diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther 21(2):66–72CrossRef

29.

Macaulay GC, Boucher SE, Yogarajah A, Galland BC, Wheeler BJ (2020) Sleep and night-time caregiving in parents of children and adolescents with Type 1 Diabetes mellitus—a qualitative study. Behav Sleep Med 18(5):622–636CrossRef

30.

Macaulay GC, Galland BC, Boucher SE, Wiltshire EJ, Haszard JJ, Campbell AJ et al (2020) Impact of Type 1 Diabetes mellitus, glucose levels, and glycemic control on sleep in children and adolescents: a case-control study. Sleep 43(2):zsz226PubMed

31.

Cobry EC, Hamburger E, Jaser SS (2020) Impact of the hybrid closed-loop system on sleep and quality of life in youth with Type 1 Diabetes and their parents. Diabetes Technol The 22(11):794–800CrossRef

32.

Bisio A, Gonder-Frederick L, McFadden R, Chernavvsky D, Voelmle M, Pajewski M et al (2021) The impact of a recently approved automated insulin delivery system on glycemic, sleep, and psychosocial outcomes in older adults with Type 1 Diabetes: a pilot study. J Diabetes Sci Technol. https://doi.org/10.1177/1932296820986879CrossRefPubMed

Title: Improved technology satisfaction and sleep quality with Medtronic MiniMed® Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial
Authors: Benjamin J. Wheeler
Olivia J. Collyns
Renee A. Meier
Zara L. Betts
Chris Frampton
Carla M. Frewen
Barbara Galland
Niranjala M. Hewapathirana
Shirley D. Jones
Denis S. H. Chan
Anirban Roy
Benyamin Grosman
Natalie Kurtz
John Shin
Robert A. Vigersky
Martin I. de Bock
Publication date: 01-01-2022
Publisher: Springer Milan
Keywords: Insulins
Hypoglycemia
Insulins
Type 1 Diabetes
Published in: Acta Diabetologica / Issue 1/2022
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-021-01789-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

High pro-neurotensin levels in individuals with type 1 diabetes associate with the development of cardiovascular risk factors at follow-up

Increased incidence of genital warts among women and men with type 1 diabetes compared with the general population—results from a nationwide registry-based, cohort study

Nutrigenetic variants and response to diet/lifestyle intervention in obese subjects: a pilot study

One in ten patients with diabetes have suicidal thoughts after 1 year of the COVID-19 pandemic: We need to talk about diabetes and mental health not only during Suicide Prevention Awareness Month

Type 1 diabetes technology management traps in a pediatric patient: not all that glitters is gold

Educational level as a cause of type 2 diabetes mellitus: Caution from triangulation of observational and genetic evidence

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials